
Brainsway (BWAY) Stock Forecast & Price Target
Brainsway (BWAY) Analyst Ratings
Bulls say
BrainsWay is expected to see continued growth and success in the coming years due to their strong financial results and focus on expansion and new indications. The company's sustainable and profitable commercial model, strong balance sheet, and promising pipeline all contribute to a positive outlook for its stock. However, risks such as competition and execution issues should be closely monitored.
Bears say
BrainsWay is continuing to execute on their minority investment program, with their deep TMS appointment volume growing significantly from Q2 to Q4 of 2025 and their goal of expanding international revenue to 30-40% within five years. However, there are potential risks associated with inconsistent commercial execution and competition in the interventional psychiatry space, as well as the upcoming introduction of Compass Pathways' psilocybin therapy. These factors could impact BrainsWay's profitability and stock performance.
This aggregate rating is based on analysts' research of Brainsway and is not a guaranteed prediction by Public.com or investment advice.
Brainsway (BWAY) Analyst Forecast & Price Prediction
Start investing in Brainsway (BWAY)
Order type
Buy in
Order amount
Est. shares
0 shares